Docaravimab + miromavimab combination is approved for medical use for treating rabies.

Docaravimab + miromavimab is prescribed for post-exposure risk prevention after contact with an infected animal or an animal suspected to have a rabies infection.

Docaravimab + miromavimab is available as an injection in two different strengths: 600IU and 1500IU. It is primarily administered intramuscularly, typically at the site of the potential rabies exposure.

Common side effects of Docaravimab + miromavimab may include localized reactions at the injection site, such as pain, swelling, redness, and a low-grade fever. Serious side effects are rare but may involve severe allergic reactions (anaphylaxis) that can result in symptoms like difficulty breathing, facial or throat swelling, hives, and a drop in blood pressure.

Docaravimab + miromavimab may risk severe allergic reactions, including anaphylaxis, which can be life-threatening. Some individuals may experience a mild increase in body temperature (low-grade fever) as a common side effect.

Before initiating the treatment, consult your healthcare professional and disclose any known allergies to similar products. During and after the treatment, keenly monitor for any adverse reactions. This injection is safe to use in children. Talk to your physician if you are pregnant or breastfeeding before taking docaravimab + miromavimab injection.

For those prescribed docaravimab + miromavimab Injection, it is crucial to prioritise safety through open communication with your healthcare provider. Adhering strictly to the prescribed dosage and schedule is paramount. If this injection is combined with a rabies vaccine, ensure compliance with the recommended vaccination schedule. Attend all scheduled follow-up appointments for proper monitoring. 

Familiarize yourself with the signs of severe reactions and seek immediate medical attention if necessary. Communicate promptly with your healthcare provider regarding any changes in your health status. If you are pregnant or planning to breastfeed, discuss your plans with your healthcare provider. Always seek personalized advice from healthcare professionals to ensure your safety during treatment.

1. Zydus; the U.S. Food And Drug Administration (FDA) [Accessed on 14/08/202] https://www.fda.gov/media/106517/download 
2. Kevinkumar Kansagra et al. A Phase 3, Randomised, Open-Label, Non-inferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG); Clinical Infectious Diseases; Published on 17/06/2020; Accessed on 14/08/2021; https://pubmed.ncbi.nlm.nih.gov/32556113/ 
3. De Melo GD et al., A combination of two human monoclonal antibodies cures symptomatic rabies; EMBO Mol Med; Published on 06/11/2020; Accessed on 13/11/2023 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645379/
4.  Anti-rabies virus monoclonal antibodies, World Health Organisation (WHO), https://list.essentialmeds.org/recommendations/1220/print?format=pdf

The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.